Literature DB >> 20372981

Diabetes-related defects in sarcoplasmic Ca2+ release are prevented by inactivation of G(alpha)11 and G(alpha)q in murine cardiomyocytes.

Dieter Paul Hoyer1, Sabine Grönke, Konrad F Frank, Klaus Addicks, Nina Wettschureck, Stefan Offermanns, Erland Erdmann, Hannes Reuter.   

Abstract

Neurohumoral stimulation of Gq-coupled receptors has been proposed as a central mechanism in the pathogenesis of diabetic heart disease. The resulting contractile dysfunction is closely related to abnormal intracellular Ca(2+) handling with functional defects of the sarcoplasmic reticulum (SR). The present study was therefore designed to determine the role of G(q)-protein signaling via G(alpha)(11) and G(alpha)(q) in diabetes for the induction of functional and structural changes in the Ca(2+) release complex of the SR. An experimental type 1-diabetes was induced in wild type, G(alpha)(11) knockout, and G(alpha)(11/q)-knockout mice by injection of streptozotocin. Cardiac morphology and function was assessed in vivo by echocardiography. SR Ca(2+) leak was tested in vitro based on a (45)Ca(2+) assay and protein densities as well as gene expression of ryanodine receptor (RyR2), FKBP12.6, sorcin, and annexin A7 were analyzed by immunoblot and RT-PCR. In wild type animals 8 weeks of diabetes resulted in cardiac hypertrophy and SR Ca(2+) leak was increased. In addition, diabetic wild type animals showed reduced protein levels of FKBP12.6 and annexin A7. In G(alpha)(11)- and G(alpha)(11/q)-knockout animals, however, SR Ca(2+) release and cardiac phenotype remained unchanged upon induction of diabetes. Densities of the proteins that we presently analyzed were also unaltered in G(alpha)(11)-knockout mice. G(alpha)(11/q)-knockout animals even showed increased expression of sorcin and annexin A7. Thus, based on the present study we suggest a signaling pathway via the G(q)-proteins, G(alpha)(11) and G(alpha)(q), that could link increased neurohumoral stimulation in diabetes with defective RyR2 channel function by regulating protein expression of FKBP12.6, annexin A7, and sorcin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372981     DOI: 10.1007/s11010-010-0454-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  35 in total

1.  PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.

Authors:  S O Marx; S Reiken; Y Hisamatsu; T Jayaraman; D Burkhoff; N Rosemblit; A R Marks
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

2.  Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryanodine receptor phosphorylation mutants.

Authors:  Mirko Stange; Le Xu; David Balshaw; Naohiro Yamaguchi; Gerhard Meissner
Journal:  J Biol Chem       Date:  2003-10-07       Impact factor: 5.157

3.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

4.  The increased angiotensin II (type 1) receptor density in myocardium of type 2 diabetic patients is prevented by blockade of the renin-angiotensin system.

Authors:  H Reuter; C Adam; S Grönke; C Zobel; K F Frank; J Müller-Ehmsen; J Brabender; R H G Schwinger
Journal:  Diabetologia       Date:  2006-10-19       Impact factor: 10.122

5.  Loss of annexin A7 leads to alterations in frequency-induced shortening of isolated murine cardiomyocytes.

Authors:  C Herr; N Smyth; S Ullrich; F Yun; P Sasse; J Hescheler; B Fleischmann; K Lasek; K Brixius; R H Schwinger; R Fässler; R Schröder; A A Noegel
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

Review 6.  Intracellular calcium release and cardiac disease.

Authors:  Xander H T Wehrens; Stephan E Lehnart; Andrew R Marks
Journal:  Annu Rev Physiol       Date:  2005       Impact factor: 19.318

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  High prevalence of echocardiographic abnormalities in diabetic youths.

Authors:  Z A Lababidi; D E Goldstein
Journal:  Diabetes Care       Date:  1983 Jan-Feb       Impact factor: 19.112

9.  Doppler echocardiographic evaluation of left ventricular diastolic function in adolescents with diabetes mellitus.

Authors:  T W Riggs; D Transue
Journal:  Am J Cardiol       Date:  1990-04-01       Impact factor: 2.778

10.  Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes.

Authors:  Dean T Eurich; Sumit R Majumdar; Ross T Tsuyuki; Jeffrey A Johnson
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

View more
  2 in total

1.  Role of RyR2 phosphorylation in heart failure and arrhythmias: Controversies around ryanodine receptor phosphorylation in cardiac disease.

Authors:  Dobromir Dobrev; Xander H T Wehrens
Journal:  Circ Res       Date:  2014-04-11       Impact factor: 17.367

2.  Annexin A7 suppresses lymph node metastasis of hepatocarcinoma cells in a mouse model.

Authors:  Yanling Jin; Shaoqing Wang; Wenjing Chen; Jun Zhang; Bo Wang; Hongwei Guan; Jianwu Tang
Journal:  BMC Cancer       Date:  2013-11-04       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.